Skip to main content

Table 2 Characteristics of included studies

From: Comparison of transcatheter aortic valve implantation with other approaches to treat aortic valve stenosis: a systematic review and meta-analysis

Study author and year Study design Risk of bias Recruitment period Study sites and country Follow-upa(Months or years) Intervention Nb TAVI device (%)h TAVI access (%)h
Reardon 2017 [9] SURTAVI RCT non-inferiority Low 2012–2016 87 USA, Canada, and Europe Max
2 years
TAVI 879
SAVR 867
Medtronic CoreValve (84)
Medtronic Evolut R (16)
TF (NR)
TS (NR)
TAO (NR)
Leon 2016 [8] PARTNER 2A RCT non-inferiority Low 2011–2013 57 USA and Canada Max
2 years
TAVI 1011
SAVR 1021
Edwards SAPIEN XT (100) TF (76.7)
TA (17.2)
TAO (6.1)
Thyregod 2015 [21] NOTION RCT superiority Low 2009–2013 2 Denmark, 1 Sweden Max
5 years
TAVI 145
SAVR 135
Medtronic CoreValve (100) TF (96.5)
TS (3.5)
Adams 2014 [7] US CoreValve RCT non-inferiority and superiority Low 2011–2012 45 USA Mean
14.1 months
12.8 months
TAVI 394
SAVR 401
Medtronic CoreValve (100) TF (82.8)
TS and TAO (17.2)
Smith 2011 [5] PARTNER A RCT non-inferiority Low 2007–2009 22 USA, 2 Canada, 1 Germany Median
1.4 years
TAVI 348
SAVR 351
Edwards SAPIEN (100) TF (70.1)
TA (29.9)
Leon 2010 [4] PARTNER B RCT superiority Low 2007–2009 21 (17 USA, 4 other) Median
1.6 years
TAVI 179
MT 179
(150 MT + BAV)
Edwards SAPIEN (100) TF (100)
Repossini 2017 [33] Observational propensity matched Low 2010–2014 7 EU Max
1 month
TAVI 142
SAVR 142
Edwards SAPIEN XT (NR)
Medtronic CoreValve (NR)
Symetis ACURATE (NR)
TF (NR)
TA (NR)
Other transvascular (NR)
Hannan 2016 [24] Observational propensity matched Medium 2011–2012 17 USA Max
1 year
TAVI 405
SAVR 405
NR TF (84.7)
TA (15.3)
D’Onofrio 2016 [23] Observational propensity matched Low 2007–2012 33 Italy Max
1 year
TAVI 214
SAVR 214e
Edwards SAPIEN (NR)
Edwards SAPIEN XT (NR)
TF (NR)
TA (NR)
Kobrin 2015 [26] Observational propensity matched Low 2011–2012 Multicenter USA Median
6.2 monthsc
TAVI 194
SAVR 194
NR NR
Tamburino 2015 [31] OBSERVANT Observational propensity matched Low 2010–2012 93 Italy Max
1 year
TAVI 650
SAVR 650
Edwards SAPIEN XT (44.9)
Medtronic CoreValve (55.1)
TF (100)
Schymik 2015 [30] Observational propensity matched Low 2008–2012 2007–2012 1 Germany Max
3 years
TAVI 216
SAVR 216
Edwards SAPIEN (NR)
Edwards SAPIEN XT (NR)
Medtronic CoreValve (NR)
Symetis ACURATE (NR)
TF (NR)
TA (NR)
Muneretto 2015d [28] Observational propensity matched Low 2007–2014 7 Europe Mean
2.7 years
4.4 years
2.3 years
TAVI 204
SAVR 408f
Edwards SAPIEN XT (38.7)
Medtronic CoreValve (59.3)
Symetis ACURATE (1.9)
TF (74.5)
TA (24.5)
Other transvessel approach (0.9)
Hoffmann 2013 [34] Observational propensity matched Low 2008–2009 1 Germany Max
2 years
TAVI 135
MT 135
(13 MT + BAV)
Edwards SAPIEN (53.3)
Medtronic CoreValve (46.7)
TA (53.3)
TF (46.7)
D’Onofrio 2013 [22] Observational propensity matched Low 2008–2011 2009–2011 Multicenter
Italy
Max
1 month
TAVI 143
SAVR 143g
Edwards SAPIEN (NR)
Edwards SAPIEN XT (NR)
TA (100)
Piazza 2013 [29] Observational propensity matched Low 2006–2010 3 (Switzerland, Germany, the Netherlands) Max
1 year
TAVI 405
SAVR 405
NR NR
Latib 2012 [27] Observational propensity matched Low 2007–2011 2003–2008 1 Italy Max
1 year
TAVI 111
SAVR 111
Edwards SAPIEN and SAPIEN XT (63.1)
Medtronic CoreValve (36.9)
TF (100)
Holzhey 2012 [25] Observational Propensity matched Low 2006–2010 2001–2010 1 Germany Mean
1.8 years
TAVI 167
SAVR 167
Edwards SAPIEN (100) TA (100)
Walther 2010 [32] Observational propensity matched Low 2006–2008 1 Germany Max
1 year
TAVI 100
SAVR 100
Edwards SAPIEN (100) TA (100)
  1. BAV balloon aortic valvuloplasty, ITT intention-to-treat population, Max maximum, MT medical therapy, N number of patients, NR not reported, SAVR surgical aortic valve replacement, TAVI transcatheter aortic valve replacement, TA transapical, TAO transaortic, TF transfemoral, TS transsubclavian, USA United States of America
  2. aIf mean or median follow-up is not available, maximum follow-up time was extracted
  3. bITT population
  4. cTAVI patients
  5. dThird treatment arm with sutureless surgical aortic valve replacement not extracted
  6. eAll patients received sutureless surgical aortic valve replacement
  7. f204 patients received sutureless aortic valve replacement
  8. g31 patients received sutureless aortic valve replacement
  9. hPercentages refer to ITT or as-treated population